Results 161 to 170 of about 67,058 (255)

Development and Validation of an Interpretable Machine Learning‐Based Clinical Prediction Model for Short‐Term Mortality in Intracerebral Hemorrhage With Thrombocytopenia: A Multicenter Study

CNS Neuroscience &Therapeutics, Volume 32, Issue 8, August 2026.
In this study, we developed and validated a clinical prediction model for the early prediction of short‐term mortality in patients with intracerebral hemorrhage complicated by thrombocytopenia. The model demonstrated good internal discrimination and acceptable external performance and may serve as a complementary tool for individualized risk ...
Dachang Qiu, Guangwei Li, Ze Wang, Lin Wang, Lanlan Wang, Yongfei Dong   +5 more
wiley   +1 more source

Myelodysplastic Syndrome (MDS) With <i>KMT2A::CBL</i> Rapidly Progressed to Acute Myeloid Leukaemia (AML). [PDF]

EJHaem
Xu K, Boneva T, Nacheva E.
europepmc   +1 more source

Amyloidosis and Myelodysplastic Syndrome

Internal Medicine, 2008
Oka, Satoko, Muroi, Kazuo, Toshima, Masaki, Nagai, Tadashi, Kanai, Nobuyuki, Morita, Tatsuo, Ozawa, Keiya   +6 more
openaire   +2 more sources

DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors

Genes, Chromosomes and Cancer, Volume 65, Issue 8, August 2026.
ABSTRACT Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas and the most common cause of disease‐associated death for neurofibromatosis type 1 (NF1) patients. In the context of NF1, MPNSTs develop from benign premalignant precursors and the transition to malignancy is typically accompanied by loss of the polycomb ...
Madilyn R. Stahl, Christopher M. Stehn, Zachary J. Seeman, Christopher Faulk, David A. Largaespada   +4 more
wiley   +1 more source

Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts. [PDF]

EJHaem
Meng S, Zhao W, Zhang H, Lei B, Zhang W, Zhang Y, Wang J, Chen Y, Cao X, Gu L.   +9 more
europepmc   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

Advances in the study of TIM3 in myelodysplastic syndrome. [PDF]

Front Immunol
Guo X, Yu S, Tao J, Wang Y, Shao Z, Fu R, Li L.   +6 more
europepmc   +1 more source

Rationale and Methods of a Surveillance System for Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies: A Qualitative Participatory Action Research Approach in Middle‐Income Countries—The Experience in Iran

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Hematopoietic Stem Cell Transplantation (HSCT) represents a cornerstone in the therapeutic management of hematological malignancies, aimed at achieving durable remission and enhancing survival. Optimal post‐transplant care, however, necessitates access to near‐real‐time, actionable clinical data.
Sima Oshnouei, Mohamad Jebraeily, Mohsen Asadi‐Lari, Babak Eshrati, Rahim Asghari, Masoumeh Nabivandrezaei, Ali Arash Anoushirvani, Aarefeh Jafarzadeh‐Kohneloo   +7 more
wiley   +1 more source

The development of intrapulmonary shunting caused by luspatercept in low grade myelodysplastic syndrome: a case report. [PDF]

AME Case Rep
Frisch A, Wilkinson JD, Nyquist AS.
europepmc   +1 more source

Myelodysplastic syndrome.

Nihon Naika Gakkai Zasshi, 1985
openaire   +3 more sources